IRIS Accounts Production v26.1.10.61 08121735 Board of Directors 6.4.25 5.4.26 5.4.26 0 0 false true false false false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh081217352025-04-05081217352026-04-05081217352025-04-062026-04-05081217352024-04-05081217352024-04-062025-04-05081217352025-04-0508121735ns15:EnglandWales2025-04-062026-04-0508121735ns14:PoundSterling2025-04-062026-04-0508121735ns10:Director12025-04-062026-04-0508121735ns10:PrivateLimitedCompanyLtd2025-04-062026-04-0508121735ns10:Micro-entities2025-04-062026-04-0508121735ns10:AuditExempt-NoAccountantsReport2025-04-062026-04-0508121735ns10:SmallCompaniesRegimeForAccounts2025-04-062026-04-0508121735ns10:FullAccounts2025-04-062026-04-0508121735ns5:CurrentFinancialInstruments2026-04-0508121735ns5:CurrentFinancialInstruments2025-04-0508121735ns10:RegisteredOffice2025-04-062026-04-0508121735ns10:Director112025-04-0508121735ns10:Director112024-04-0508121735ns10:Director112025-04-062026-04-0508121735ns10:Director112024-04-062025-04-0508121735ns10:Director112026-04-0508121735ns10:Director112025-04-05
REGISTERED NUMBER: 08121735 (England and Wales)















KAS PHARMA LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED

5TH APRIL 2026






KAS PHARMA LIMITED (REGISTERED NUMBER: 08121735)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5TH APRIL 2026










Page

Statement of Financial Position 1 to 2


KAS PHARMA LIMITED (REGISTERED NUMBER: 08121735)

STATEMENT OF FINANCIAL POSITION
5TH APRIL 2026

2026 2025
£    £    £    £   
FIXED ASSETS 2,445 582

CURRENT ASSETS 319,869 275,064

CREDITORS
Amounts falling due within one year (32,965 ) (31,899 )
NET CURRENT ASSETS 286,904 243,165
TOTAL ASSETS LESS CURRENT
LIABILITIES

289,349

243,747

ACCRUALS AND DEFERRED INCOME (1,792 ) (1,746 )
NET ASSETS 287,557 242,001

CAPITAL AND RESERVES 287,557 242,001

NOTES TO THE FINANCIAL STATEMENTS

1. STATUTORY INFORMATION

KAS Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 08121735

Registered office: 43-45 Devizes Road
SWINDON
Wiltshire
SN1 4BG

2. AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the year was NIL (2025 - NIL).

3. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 5th April 2026 and 5th April 2025:

2026 2025
£    £   
Mr K A Symcox
Balance outstanding at start of year 4,575 3,287
Amounts advanced 5,339 4,887
Amounts repaid (4,887 ) (3,599 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 5,027 4,575

The above loan was provided interest free and was repaid in full on 17th June 2026.



KAS PHARMA LIMITED (REGISTERED NUMBER: 08121735)

STATEMENT OF FINANCIAL POSITION - continued
5TH APRIL 2026


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 5th April 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 5th April 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 9th July 2026 and were signed on its behalf by:





Mr K A Symcox - Director